Who's the next Dendreon?

One popular new game in biotech investment circles is guessing the cancer vaccine developer that is most likely to follow in the footsteps of Dendreon (NASDAQ: DNDN), which braved some considerable challenges to bring Provenge to the market. But Trista Morrison at BNET dashes the fevered speculation with a bucket of cold water, noting that the road to Provenge's approval was littered with the burned wreckage of failed rivals. This is an extremely complex field that didn't get any easier to work in now that Provenge is coming to the market. And the second approval will require long years of development work. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.